血管內(nèi)皮生長因子受體2(VEGFR2)多克隆抗體
Polyclonal Antibody to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1
- 編號UPAB367Po01
- 物種Sus scrofa; Porcine (Pig，豬) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 RPB367Po01-血管內(nèi)皮生長因子受體2(VEGFR2)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度0.5mg/mL
- 且適物種Homo sapiens (Human，人)
- 應用ICC/IF
如果抗體需用于流式細胞術(shù)，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 360 ¥ 840 ¥ 1200 ¥ 3000 ¥ 12000
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
FITC staining on IF; Sample: Human MCF7 cell; Primary Ab: 20ug/ml Rabbit Anti-Porcine VEGFR2 Antibody Second Ab: 2μg/ml FITC-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb18)
-
Figure. Western Blot; Sample: Recombinant VEGFR2, Porcine.
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
該抗體是針對VEGFR2的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別VEGFR2。
用法
Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Sus scrofa; Porcine (Pig，豬) | 應用(僅供研究使用，不用于臨床診斷！) |
| URPB367Po01 | 血管內(nèi)皮生長因子受體2(VEGFR2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAB367Po01 | 血管內(nèi)皮生長因子受體2(VEGFR2)多克隆抗體 | ICC/IF |
| UMAB367Po21 | 血管內(nèi)皮生長因子受體2(VEGFR2)單克隆抗體 | WB; IHC; ICC; IP. |
| USEB367Po | 血管內(nèi)皮生長因子受體2(VEGFR2)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMB367Po | 血管內(nèi)皮生長因子受體2(VEGFR2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| APMIS | Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway [PubMed: 23398358] |
| Acta Biomater | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study [PubMed: 26689470] |
| Acta Biomaterialia | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study [Pubmed:26689470] |
| Journal?of?Cellular?Physiology | A?Human?3D?In?Vitro?Model?to?Assess?the?Relationship?Between?Osteoporosis?and?Disseminationto?Bone?of?Breast?Cancer?Tumor?Cells. [pubmed:27925188] |
| Regenerative Biomaterials | The directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic [10.1093/rb/rbx028] |
| International Journal of Immunopathology and Pharmacology | VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these?… [Pubmed:29985074] |
| JOURNAL OF DERMATOLOGICAL TREATMENT | Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris [Pubmed: 32043381] |
| Journal of Genetic Engineering and Biotechnology | Encapsulated VEGF 121-PLA microparticles promote angiogenesis in human endometrium stromal cells [33523322] |
| Mol Cell Biochem | Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy [34324118] |
| BMC Nephrol | Effect of subacute poisoning with lambdacyhalothrin on vascular endothelial growth factor 2 receptor in mice kidneys [Pubmed:35643467] |
留言咨詢
